Korro Bio, Inc. (KRRO)
12.28
-0.75
(-5.76%)
USD |
NASDAQ |
Jul 16, 16:00
12.31
+0.03
(+0.24%)
Pre-Market: 09:19
Korro Bio Debt to Equity Ratio : 0.3585 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.3585 |
| December 31, 2025 | 0.8454 |
| September 30, 2025 | 0.451 |
| June 30, 2025 | 0.3878 |
| March 31, 2025 | 0.3252 |
| December 31, 2024 | 0.2791 |
| September 30, 2024 | 0.2326 |
| June 30, 2024 | 0.1942 |
| March 31, 2024 | 0.2373 |
| December 31, 2023 | 0.1954 |
| September 30, 2023 | 0.0388 |
| June 30, 2023 | 0.6124 |
| March 31, 2023 | 0.7506 |
| December 31, 2022 | -1.686 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.5397 |
| June 30, 2022 | 0.4662 |
| March 31, 2022 | 0.401 |
| December 31, 2021 | 0.3485 |
| September 30, 2021 | 0.3126 |
| June 30, 2021 | 0.2793 |
| March 31, 2021 | 0.262 |
| December 31, 2020 | 0.2389 |
| September 30, 2020 | 0.0112 |
| June 30, 2020 | 0.0145 |
| March 31, 2020 | 0.0148 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | -2.479 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.237 |
| Oncolytics Biotech, Inc. | -0.099 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6888 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 183.62M |
| Total Liabilities (Quarterly) | 63.99M |
| Shareholders Equity (Quarterly) | 119.63M |
| Current Ratio | 8.126 |
| Net Debt Paydown Yield | 0.23% |